chlorpromazine has been researched along with aripiprazole in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.35) | 18.2507 |
| 2000's | 8 (34.78) | 29.6817 |
| 2010's | 10 (43.48) | 24.3611 |
| 2020's | 4 (17.39) | 2.80 |
| Authors | Studies |
|---|---|
| Kikuchi, T; Kurahashi, N; Nishi, T; Oshiro, Y; Sato, S; Tanaka, T; Tottori, K; Uwahodo, Y | 1 |
| Ernsberger, P; Hufeisen, SJ; Jayathilake, K; Kroeze, WK; Meltzer, HY; Popadak, BA; Renock, SM; Roth, BL; Steinberg, S | 1 |
| Glennon, RA | 1 |
| Coolen, HK; Glennon, JC; Kruse, CG; Lange, JH; Reinders, JH; Tolboom, JT | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Sen, S; Sinha, N | 1 |
| Chang, G; Di, L; Huang, Y; Lin, Z; Liston, TE; Scott, DO; Troutman, MD; Umland, JP | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bienkowski, P; Bucki, A; Jaśkowska, J; Kazek, G; Kowalski, P; Kołaczkowski, M; Marcinkowska, M; Mierzejewski, P; Mitka, K; Pawłowski, M; Siwek, A; Wasik, A; Wesołowska, A | 1 |
| Bienkowski, P; Bucki, A; Jastrzębska-Więsek, M; Kazek, G; Kołaczkowski, M; Marcinkowska, M; Mierzejewski, P; Partyka, A; Pawłowski, M; Siwek, A; Śniecikowska, J; Wasik, A; Wesołowska, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bucki, A; Głuch-Lutwin, M; Jakubczyk, M; Jamrozik, M; Jastrzębska-Więsek, M; Kołaczkowski, M; Marcinkowska, M; Mierzejewski, P; Partyka, A; Pawłowski, M; Pytka, K; Siwek, A; Śniecikowska, J; Wesołowska, A; Zagórska, A | 1 |
| Bojarski, AJ; Dehaen, W; Janousek, J; Juza, R; Karasova, JZ; Kobrlova, T; Korabecny, J; Kubacka, M; Mezeiova, E; Mogilski, S; Musilek, K; Pejchal, J; Petrasek, T; Prchal, L; Randakova, A; Satala, G; Soukup, O; Stark, H; Stefkova-Mazochova, K; Svozil, D; Vlcek, P; Vojtechova, I | 1 |
| Kalkman, HO; Loetscher, E | 1 |
| Woods, SW | 1 |
| Balit, CR; Isbister, GK; Kilham, HA | 1 |
| Cooper, T; Usubiaga, H; Winsberg, B | 1 |
| Beck, A; Dembler, T; Dinges, M; Friedel, E; Gallinat, J; Heinz, A; Juckel, G; Sarkar, R; Schlagenhauf, F; Wrase, J; Wüstenberg, T | 1 |
| Cao, B; Hou, R; Jian, J; Mi, G; Qiu, H; Tang, M; Wang, M | 1 |
| Cassoli, JS; Guest, PC; Martins-de-Souza, D; Santana, AG | 1 |
| Goldman, J; Kanzali, P; Paras, C; Rubin, V; Zhang, F | 1 |
| Osman, E; Yıldız, M | 1 |
| Davies, SJ; Nutt, DJ; Zhou, C | 1 |
5 review(s) available for chlorpromazine and aripiprazole
| Article | Year |
|---|---|
Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7).
Topics: Animals; Humans; Ligands; Receptors, Serotonin; Serotonin Agents; Serotonin Antagonists; Serotonin Receptor Agonists | 2003 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Chlorpromazine equivalent doses for the newer atypical antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chlorpromazine; Dibenzothiazepines; Dose-Response Relationship, Drug; Drug Administration Schedule; Haloperidol; Humans; Olanzapine; Piperazines; Pirenzepine; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Therapeutic Equivalency; Thiazoles | 2003 |
Antipsychotic poisoning in young children: a systematic review.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Child, Preschool; Chlorpromazine; Clozapine; Dibenzothiazepines; Haloperidol; Humans; Infant; Infant, Newborn; Olanzapine; Pimozide; Piperazines; Poisoning; Quetiapine Fumarate; Quinolones; Risperidone | 2005 |
Employing proteomics to unravel the molecular effects of antipsychotics and their role in schizophrenia.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Brain; Chlorpromazine; Clozapine; Disease Models, Animal; Gene Expression Regulation; Glycolysis; Humans; Mitochondrial Proteins; Nerve Tissue Proteins; Oxidative Phosphorylation; Proteome; Proteomics; Schizophrenia; Treatment Outcome | 2016 |
1 trial(s) available for chlorpromazine and aripiprazole
| Article | Year |
|---|---|
Ghrelin and leptin response to oral glucose challenge among antipsychotic drug-treated children.
Topics: Administration, Oral; Adolescent; Age Factors; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; Blood Glucose; Body Mass Index; Child; Chlorpromazine; Fasting; Female; Ghrelin; Glucose; Glucose Tolerance Test; Humans; Insulin; Leptin; Male; Piperazines; Quinolones; Risperidone; Sex Factors; Time Factors; Weight Gain | 2007 |
17 other study(ies) available for chlorpromazine and aripiprazole
| Article | Year |
|---|---|
Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis and pharmacology of 7-[4-(4-phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone derivatives.
Topics: 4-Butyrolactone; Animals; Antipsychotic Agents; Apomorphine; Aripiprazole; Brain; Catalepsy; Dihydroxyphenylalanine; Dopamine Agonists; Dopamine Antagonists; GABA Modulators; Male; Mice; Mice, Inbred ICR; Molecular Structure; Piperazines; Quinolones; Rats; Stereotyped Behavior; Structure-Activity Relationship | 1998 |
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.
Topics: Animals; Antipsychotic Agents; Discriminant Analysis; Drug Evaluation, Preclinical; Forecasting; Humans; Protein Binding; Receptors, Histamine H1; Statistics, Nonparametric; Weight Gain | 2003 |
Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzoxazines; Biogenic Monoamines; Humans; Hyperprolactinemia; Indoles; Metabolic Diseases; Phthalimides; Piperazines; Principal Component Analysis; Pyridines; Radioligand Assay; Receptors, Biogenic Amine; Weight Gain | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
Species independence in brain tissue binding using brain homogenates.
Topics: Animals; Brain; Dogs; Guinea Pigs; Humans; Macaca fascicularis; Mice; Rats; Species Specificity | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Avoidance Learning; Benzoxazoles; Catalepsy; CHO Cells; Cricetulus; Dementia; Dopamine D2 Receptor Antagonists; HEK293 Cells; Humans; Male; Models, Molecular; Motor Activity; Radioligand Assay; Rats, Wistar; Receptors, Serotonin; Serotonin Antagonists; Structure-Activity Relationship; Sulfonamides | 2014 |
Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia.
Topics: Animals; Benzamides; Dementia; Dose-Response Relationship, Drug; Drug Partial Agonism; Humans; Indoles; Ligands; Male; Models, Molecular; Molecular Structure; Piperazines; Quinolones; Rats; Rats, Wistar; Receptors, Dopamine D2; Receptors, Serotonin; Structure-Activity Relationship; Swimming | 2015 |
Multifunctional 6-fluoro-3-[3-(pyrrolidin-1-yl)propyl]-1,2-benzoxazoles targeting behavioral and psychological symptoms of dementia (BPSD).
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Benzoxazoles; Dementia; Dizocilpine Maleate; Dose-Response Relationship, Drug; Ether-A-Go-Go Potassium Channels; Humans; Male; Mice; Models, Molecular; Molecular Structure; Structure-Activity Relationship | 2020 |
Novel D
Topics: Animals; Antipsychotic Agents; Piperazines; Rats; Rats, Wistar; Receptors, Serotonin; Schizophrenia | 2022 |
alpha2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brimonidine Tartrate; Chlorpromazine; CHO Cells; Clozapine; Cricetinae; Cyclic AMP; Dibenzothiazepines; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Gene Expression; Haloperidol; Humans; Isoxazoles; Norepinephrine; Olanzapine; Piperazines; Piperidines; Pirenzepine; Quetiapine Fumarate; Quinolones; Quinoxalines; Receptors, Adrenergic, alpha-2; Receptors, Dopamine D2; Risperidone; Thiazoles; Transfection; Yohimbine | 2003 |
Switching schizophrenia patients from typical neuroleptics to aripiprazole: effects on working memory dependent functional activation.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Brain Mapping; Chlorpromazine; Female; Gyrus Cinguli; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Memory Disorders; Memory, Short-Term; Middle Aged; Neuropsychological Tests; Oxygen; Photic Stimulation; Piperazines; Quinolones; Reaction Time; Schizophrenia; Schizophrenic Psychology; Time Factors; Visual Cortex; Young Adult | 2010 |
Effects of antipsychotics on bone mineral density and prolactin levels in patients with schizophrenia: a 12-month prospective study.
Topics: Adult; Alkaline Phosphatase; Antipsychotic Agents; Aripiprazole; Bone Density; Chlorpromazine; Clozapine; Dibenzothiazepines; Estrogens; Female; Humans; Male; Middle Aged; Osteoporosis; Perphenazine; Piperazines; Prolactin; Prospective Studies; Quetiapine Fumarate; Quinolones; Risk Factors; Schizophrenia; Sulpiride | 2014 |
Neuroleptic malignant syndrome with thyroid disorder: An unusual case report.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Chlorpromazine; Creatine Kinase; Diagnosis, Differential; Drug Substitution; Fluid Therapy; Humans; Hypothyroidism; Male; Neuroleptic Malignant Syndrome; Schizophrenia, Paranoid; Thyroid Nodule; Thyrotropin; Treatment Outcome | 2017 |
Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
Topics: Adenosine Monophosphate; Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chlorpromazine; Clopenthixol; Clozapine; Flupenthixol; Fluphenazine; Haloperidol; Humans; Olanzapine; Paliperidone Palmitate; Pharmaceutical Preparations; Pimozide; Quetiapine Fumarate; Risperidone; Sulpiride; Trifluoperazine | 2022 |
Visualizing classification of drugs used in psychotic disorders: A 'subway map' representing mechanisms, established classes and informal categories.
Topics: Antipsychotic Agents; Aripiprazole; Butyrophenones; Chlorpromazine; Dopamine; Dopamine Agonists; Histamine; Humans; Psychotic Disorders; Railroads; Receptors, Dopamine D2; Systematic Reviews as Topic | 2022 |